

**North Dakota Medicaid
DUR Board Meeting Agenda
Pioneer Room
State Capitol
600 East Boulevard Avenue
Bismarck, ND
September 2, 2015
1pm**

1. Administrative items
 - Travel vouchers
2. Old business
 - Review and approval of minutes of 06/15 meeting
 - Budget update
 - Review top 15 therapeutic categories/top 25 drugs
 - Second review cholesterol lowering drugs
 - Second review of injectable anticoagulants
 - Second review of Akynzeo
 - Second review of Nuessa
 - Second review of Cholbam
 - Update on drugs added to > \$3,000 prior authorization (Natpara)
3. New business
 - Sanford Health Plan expansion update
 - Prior authorization updates on current drugs/classes
 - Review of Movantik (naloxegol)
 - Review of Marinol (dronabinol)
 - Review of skin pigment products (hydroquinone)
 - Review of inhaled corticosteroid/long-acting beta-2 adrenergic agonist combination products (budesonide/formoterol, fluticasone/vilanterol, fluticasone/salmeterol, mometasone/formoterol)
 - Review of medications used to treat irritable bowel syndrome (eluxadoline, linaclotide, lubiprostone)
 - Review of medications used to treat ulcerative colitis (balsalazide, mesalamine, olsalazine, sulfasalazine)
 - Review of sodium-glucose co-transporter 2 inhibitors (canagliflozin, dapagliflozin, empagliflozin)
 - Review of immediate release oxycodone
 - Review of immediate release narcotics used in conjunction with immediate release narcotic combinations
 - Review of inhaled anti-infectives for cystic fibrosis (tobramycin, aztreonam)
 - Review of leukotriene modifiers (montelukast, zafirlukast, zileuton)
 - Gabapentin update
 - Criteria recommendations
 - Upcoming meeting date/agenda
4. Adjourn

Please remember to silence all cellular phones during the meeting.